Miriam Tucker

Miriam E. Tucker is a freelance journalist based in the Washington, DC, area. She is a regular contributor to Medscape, with other work appearing in The Washington Post, NPR’s Shots blog, and Diabetes Forecast magazine. She is on Twitter: @MiriamETucker. For more than two decades, Tucker has covered health care policy and medicine for a variety of publications. Her work has focused on the intersection of politics and health, including the Affordable Care Act’s implementation and repeal attempts, drug pricing battles, opioid addiction coverage, and vaccine hesitancy. In addition to her journalism career, Tucker has taught journalism at American University in Washington, DC. Tucker holds a bachelor’s degree in English from the University of Virginia and a master’s degree in journalism from Columbia University.

Biography:  https://www.medscape.com/viewarticle/996102

70%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

0%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

95%

Examples:

  • Between 2011 and 2014, approximately 65% of new GLP-1 users had Type 2 diabetes. This figure dropped to 57% between 2019 and 2023.
  • The proportion of new GLP-1 users with a BMI of 30 or higher rose from nearly 47% to over 66%.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

GLP-1 Receptor Agonists Shift from Diabetes to Obesity Treatment: Implications and Trends

GLP-1 Receptor Agonists Shift from Diabetes to Obesity Treatment: Implications and Trends

Broke On: Tuesday, 23 July 2024 Since around 2020, GLP-1 receptor agonists (GLP-1 RAs) have seen a notable shift from treating type 2 diabetes to obesity in the US. This trend is driven by FDA approvals and the high prevalence of obesity, accounting for over 88% of new prescriptions being semaglutide. However, this shift raises concerns about potential drug shortages and disparities in access.